Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX

Posted by Francis Steltz on Aug 15th, 2026

Summit Global Investments bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,182 shares of the pharmaceutical company’s stock, valued at approximately $3,568,000.

A number of other hedge funds have also modified their holdings of the business. Community Financial Services Group LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $26,000. Motiv8 Investments LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter valued at about $26,000. Elevation Wealth Partners LLC raised its holdings in Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 28 shares during the last quarter. Swiss RE Ltd. acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, IMG Wealth Management Inc. lifted its stake in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 50 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Stifel Nicolaus set a $500.00 target price on Vertex Pharmaceuticals in a report on Tuesday, August 4th. Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Royal Bank Of Canada lifted their price objective on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Cantor Fitzgerald upped their target price on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, TD Cowen raised their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $563.50.

Read Our Latest Stock Report on Vertex Pharmaceuticals

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 1,500 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares in the company, valued at approximately $23,793,071.79. This trade represents a 3.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 596 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $482.50, for a total value of $287,570.00. Following the transaction, the chief marketing officer directly owned 15,337 shares of the company’s stock, valued at approximately $7,400,102.50. This represents a 3.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 10,464 shares of company stock valued at $4,959,397 in the last quarter. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $505.75 on Friday. The firm has a 50 day moving average price of $483.26 and a 200 day moving average price of $463.76. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $374.17 and a fifty-two week high of $546.17. The company has a market capitalization of $128.36 billion, a PE ratio of 29.44, a price-to-earnings-growth ratio of 2.14 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01). The business had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.Vertex Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the company earned $4.52 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.86 earnings per share for the current year.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.